Yet another Schizo and MDD drug approved by FDA this week in an already crowded market.
Inspiring to see that SOME companies out there know how to launch a drug with multiple indications at the starting line! Why didn't we do that???
Impressive AE profile and efficacy data versus Latuda...with the only exception being weight gain for Rexulti
http://ift.tt/1RvlTnY
Inspiring to see that SOME companies out there know how to launch a drug with multiple indications at the starting line! Why didn't we do that???
Impressive AE profile and efficacy data versus Latuda...with the only exception being weight gain for Rexulti
http://ift.tt/1RvlTnY
Bye Bye Latuda...Hello Rexulti (brexpiprazole)
Aucun commentaire:
Enregistrer un commentaire